Long-Term Immunotherapy for ASPS: AACR 2026 Breakthrough in Rare Cancer Treatment

In this episode, we break down the latest AACR 2026 breakthrough on long-term immunotherapy for alveolar soft part sarcoma (ASPS), a rare cancer that primarily affects adolescents and young adults. You’ll learn: What ASPS is and why it has been difficult to treat How immunotherapy is changing the landscape for rare cancers Key findings from the Phase II trial using atezolizumab Why long-term immunotherapy beyond two years may be safe and effective How patients maintained d...